title: Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients.
abstract: Scientific communications indicate the disturbed expression of neuropeptides in the skin and serum in psoriasis vulgaris (PsV) patients. Narrow-band ultraviolet radiation (NB-UVB) is one of the systemic therapies of PsV. The aim of the study was to evaluate the influence of NB-UVB therapy on substance P (SP), calcitonin gene-related peptide (CGRP), brain-derived neurotrophic factor (BDNF), corticotropin-releasing factor (CRF) and interleukin-31 (IL-31) serum concentrations in PsV patients. 59 psoriatic patients with mean PASI (psoriasis area and severity index) 14.3 were treated with NB-UVB (20 exposures). The control group consisted of 50 healthy subjects, whose age and sex matched. In all patients, serum concentration of BDNF, CRF, IL-31 substance P and CGRP was analyzed by ELISA before the treatment and in psoriatic group the analysis was also done after 10 and 20 irradiations. In patients there was found a significantly higher concentration of IL-31 (215.3 vs. 748.6 ng/ml; p < 0.0001), SP (25.7 vs. 67.2 pg/ml; p < 0.01), CGRP (31.4 vs. 44.15 pg/ml; p < 0.01) and a lower concentration of CRF (0.89 vs. 0.426 ng/ml; p < 0.0001) and BDNF (16.39 vs. 14.15 ng/ml; p = 0.1216) in comparison with the controls. 20 NB-UVB exposures caused a significant decrease in IL-31 level (748.6 vs. 631.7 ng/ml; p < 0.0001). The NB-UVB therapy had no major effect on neuropeptides serum levels regardless of a number of irradiations. On the basis of our study it can be suggested that IL-31 is involved in pathogenesis of psoriasis and the NB-UVB therapy causes alterations in its level.
authors.affiliation: Department of Dermatology, Medical University of Lodz, 5 Krzemieniecka, 94-017, Lodz, Poland. joanna.narbutt@umed.lodz.pl
authors.forename: Joanna
authors.initials: J
authors.lastname: Narbutt
authors.forename: Irmina
authors.initials: I
authors.lastname: Olejniczak
authors.forename: Dorota
authors.initials: D
authors.lastname: Sobolewska-Sztychny
authors.forename: Anna
authors.initials: A
authors.lastname: Sysa-Jedrzejowska
authors.forename: Iwona
authors.initials: I
authors.lastname: Słowik-Kwiatkowska
authors.forename: Tomasz
authors.initials: T
authors.lastname: Hawro
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Lesiak
mesh_terms: D000328:Adult; D019208:Brain-Derived Neurotrophic Factor / Q000097:blood; D015740:Calcitonin Gene-Related Peptide / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000097:blood; D005260:Female; D006801:Humans; D007378:Interleukins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011537:Pruritus / Q000097:blood / Q000532:radiotherapy*; D011565:Psoriasis / Q000097:blood / Q000532:radiotherapy*; D012867:Skin / Q000528:radiation effects; D013373:Substance P / Q000097:blood; D011795:Surveys and Questionnaires; D014466:Ultraviolet Rays; D014467:Ultraviolet Therapy
chemical_list: D019208:Brain-Derived Neurotrophic Factor; C502187:IL31 protein, human; D007378:Interleukins; D013373:Substance P; C579455:BDNF protein, human; D003346:Corticotropin-Releasing Hormone; D015740:Calcitonin Gene-Related Peptide